Workflow
10x Genomics (TXG) Surpasses Q2 Earnings and Revenue Estimates
10x Genomics10x Genomics(US:TXG) ZACKS·2025-08-07 22:36

Core Viewpoint - 10x Genomics reported quarterly earnings of $0.28 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.35 per share, marking an earnings surprise of +180.00% [1][2] Financial Performance - The company posted revenues of $172.91 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 24.00% and showing an increase from $153.1 million in the same quarter last year [2] - Over the last four quarters, 10x Genomics has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance - 10x Genomics shares have declined approximately 11.8% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating expectations of outperforming the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.25 on revenues of $144.82 million, and for the current fiscal year, it is -$1.12 on revenues of $593.29 million [7] - The trend of estimate revisions for 10x Genomics was favorable ahead of the earnings release, suggesting potential positive movements in stock performance [6] Industry Context - The Medical Info Systems industry, to which 10x Genomics belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]